TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28422539
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (NIT) 140 mL daily for 3 days
Study: 28531113
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Policaptil Gel Retard® (PGR)
Study: 21539743
Drug: CURB65-A risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CURB65-A risk class I (CURB65 score 0-1 and ProADM ≤0.75 nmol/l)
Study: 21539743
Drug: CURB65-A risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CURB65-A risk class II (CURB65 score 2 and ProADM ≤1.5 nmol/l or CURB classes 0-1 and ProADM levels between 0.75-1.5 nmol/L)
Study: 21539743
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment for CURB65-A risk class I
Study: 14605970
Drug: Flexible multiple
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible multiple daily insulin (FMDI) regimen
Study: 9364627
Drug: 50.4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.4 Gy schedule (2 x 1.8 Gy/day to a total dose of 50.4 Gy)
Study: 9364627
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy schedule (2 x 2.5 Gy/day to a total dose of 30 Gy)
Study: 9364627
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (1 daily fraction of 3 Gy up to 30 Gy)
Study: 21129235
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation (1.48 g EPA+DHA/d) for 12 weeks
Study: 10992830
Drug: Patient-controlled i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled i.v. morphine alone (control)
Study: 8787884
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg (normotensive)
Study: 8787884
Drug: Valaciclovir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1,000 mg (normotensive)
Study: 8787884
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg (hypertensive)
Study: 3883493
Drug: Adriamycin administered
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin administered at 6 p.m. followed by cisplatin at 6 a.m.
Study: 3883493
Drug: Adriamycin administered
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin administered at 6 a.m. followed by cisplatin at 6 p.m.
Study: 27258524
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 μg/kg for 10 minutes, followed by continuous infusion at 0.5 μg/kg/h until 30 minutes before the end of surgery)
Study: 11110739
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving treatment (n=128)
Study: 28403084
Drug: Gabapentin alone
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin alone (group G)
Study: 26254845
Drug: High-dose carotenoid-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Study: 26254845
Drug: Low-dose carotenoid-rich
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose carotenoid-rich juice (2.75 mg carotenoids/30 mL juice)
Study: 22364094
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) irrigation with sequential irrigation of 3% H2O2, 5.2% NaOCl and 0.9% NaCl
Study: 22364094
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly mentioned, but implied to be the other treatment group)
Study: 19095827
Drug: 4% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% human albumin solution
Study: 17005272
Drug: Simvastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20-40 mg/day) for 8 weeks
Study: 12411457
Drug: Canrenone 50
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 50 mg/d
Study: 12411457
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and calcium antagonists (baseline treatment)
Study: 9857348
Drug: (re)treatment during
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: (re)treatment during long-term follow-up
Study: 8580556
Drug: Continuous injection
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous injection of isosorbide dinitrate (ISDN) at 10 mg/h
Study: 8580556
Drug: Intermittent injection
Normalized name: Jelco Intermittent Injection Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent injection of isosorbide dinitrate (ISDN) at 10 mg/10 min every 2 hours
Study: 2213778
Drug: 80 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms triiodothyronine (T3) daily
Study: 362282
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A therapy (vitamin A palmitate or 13‐cis vitamin A acid)
Study: 23459487
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bedaquiline
Study: 23459487
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bedaquiline
Study: 23459487
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg bedaquiline
Study: 23459487
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bedaquiline
Study: 15001964
Drug: Oral sustained‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained‐release morphine, 1.9 mg/kg every 12 hours
Study: 15001964
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of morphine at 0.04 mg/kg/hour
Study: 15001964
Drug: Oral sustained‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained‐release morphine
Study: 7918140
Drug: Quinapril (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (5-40 mg qd for MRI; 2.5-20 mg qd for CRF)
Study: 2561750
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) administered at one 7500, 15000 or 30000 AXaU vial/day sc for 60 days
Study: 2561750
Drug: Heparin calcium
Normalized name: HEPARIN CALCIUM
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin calcium administered at one or two 12500 IU vials/day sc for 60 days
Study: 24651682
Drug: Lycopene intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene intervention (29.4 mg of lycopene per day via 11.5 oz of V8 100% vegetable juice for 30 days)
Study: 20156067
Drug: Low-insulin step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-insulin step of the clamp in normal nonobese women
Study: 20156067
Drug: High-insulin step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-insulin step in normal nonobese women
Study: 12039991
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d sulodexide for 4 months
Study: 12039991
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d sulodexide for 4 months
Study: 12039991
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d sulodexide for 4 months
Study: 12039991
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d sulodexide at T8
Study: 2183405
Drug: Warfarin (prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (prothrombin time of 1.3‐1.8 times control)
Study: 7058441
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with various therapeutic agents
Study: 29101128
Drug: PSORI‐CM01 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSORI‐CM01 granules (5.5 g, two times daily)
Study: 29101128
Drug: Yinxieling tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinxieling tablets (five tablets, three times daily)
Study: 25691622
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin at bedtime
Study: 25691622
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin on awakening
Study: 21088598
Drug: TCI sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI sufentanil (0.3 ng ml⁻¹)
Study: 21088598
Drug: TCI remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI remifentanil (3 ng ml⁻¹)
Study: 17192828
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (Actrapid)
Study: 10813588
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (30 g)
Study: 8665191
Drug: Single-dose ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin prophylaxis for hernia repair
Study: 8665191
Drug: Single-dose ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin prophylaxis for ectopic pregnancy
Study: 8665191
Drug: Single-dose ampicillin-metronidazole
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin-metronidazole prophylaxis for hysterectomy
Study: 8665191
Drug: Single-dose ampicillin-metronidazole
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin-metronidazole prophylaxis for caesarean section
Study: 8665191
Drug: Single-dose ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ampicillin prophylaxis with or without metronidazole
Study: 8665191
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative penicillin therapy (control)
Study: 6384863
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of daily 0.5 X 10(6) IE fibroblast interferon/kg body weight for 3-5 days
Study: 25211285
Drug: CCaV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCaV at 120 CC per min
Study: 25211285
Drug: CCaV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCaV at 90 CC per min
Study: 18824331
Drug: SAM-e (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM-e (800 mg)
Study: 8387940
Drug: Men consuming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men consuming 10 g and 30 g of dietary fibre
Study: 8387940
Drug: Women consuming
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women consuming 10 g and 30 g of dietary fibre
Study: 3540223
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) verapamil (80 to 120 mg TID)
Study: 3540223
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) verapamil (equivalent dose to IR)
Study: 3330987
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) verapamil
Study: 3330987
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) verapamil
Study: 30109784
Drug: Calcium-Polystyrene Sulfonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-Polystyrene Sulfonate (Ca-PS) 3 × 5 g/day for 3 weeks
Study: 12821234
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (median dose 120 microg four times a day)
Study: 10813099
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of ethinyl estradiol (EE) and 1 mg of norethindrone (NET) from days 6 through 10 (Group I)
Study: 10813099
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of ethinyl estradiol (EE) and 1 mg of norethindrone (NET) from days 8 through 12 (Group II)
Study: 1649148
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of beta‐IFN through an Ommaya reservoir
Study: 1649148
Drug: beta‐IFN followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐IFN followed by systemic chemotherapy (Cisplatin + Etoposide)
Study: 6439234
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) administered as a dry powder via the spinhaler
Study: 30412077
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 0.8 μg/kg, pumped for over 10 minutes)
Study: 19658043
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day Zn as Zn sulfate
Study: 9872200
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (ST)
Study: 8551652
Drug: Arginine aspartate
Normalized name: Arginine aspartate
DrugBank: Arginine aspartate (DB15993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine aspartate (17 g free arginine)
Study: 2164652
Drug: 50% trichloroacetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% trichloroacetic acid (single topical application)
Study: 2164652
Drug: Saline (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo, single topical application)
Study: 25925019
Drug: Upper thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper thoracic manipulation (single session administered to the T1 vertebral area)
Study: 29188387
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg b.i.d.
Study: 12576428
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 or 600 mg/day)
Study: 11314831
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 microg/kg), midazolam (0.05 to 0.075 mg/kg), and propofol (10 to 20 mg boluses as required)
Study: 9173635
Drug: Community psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community psychiatric treatment
Study: 9173635
Drug: Control district
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control district (no community psychiatric treatment)
Study: 7892802
Drug: PREP for
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREP for Effective Family Living Program (treatment group)
Study: 3295380
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin treatment at a dose of 164.50 +/- 24.55 mg/kg body weight
Study: 3295380
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin treatment at a dose of 359.65 +/- 58.62 mg/kg body weight
Study: 3295380
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin treatment
Study: 2285464
Drug: ORS‐90 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS‐90 (oral rehydration solution recommended by WHO)
Study: 2285464
Drug: ORS‐60 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS‐60 (60 mmol/L sodium and 90 mmol/L glucose)
Study: 16800
Drug: Antidepressant 1
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant 1
Study: 16800
Drug: Antidepressant 2
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant 2
Study: 16800
Drug: Antidepressant 3
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant 3
Study: 16800
Drug: Antidepressant 4
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant 4
Study: 16800
Drug: Antidepressant 5
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant 5
Study: 16800
Drug: Antidepressant 6
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant 6
Study: 27829521
Drug: Infants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants with preoperative serum chloride < 100mmol/L
Study: 26077436
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 2% solution (40.4 mg/2 mL) BID for 7.5 days
Study: 26077436
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 1.5% solution (19.3 mg/40 drops) QID for 7.5 days
Study: 26077436
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium 75 mg BID for 7.5 days
Study: 23790158
Drug: Parent ratings
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent ratings of adolescents’ daily behaviors associated with executive functioning (EF)
Study: 21860559
Drug: DA-9601 60
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-9601 60 mg three times daily
Study: 21860559
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 µg three times daily
Study: 17092740
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg oral dose
Study: 8888028
Drug: Sodium ozagrel
Normalized name: Ozagrel
DrugBank: Ozagrel (DB12017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ozagrel (160 mg/day for two weeks)
Study: 6220603
Drug: Moxalactam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxalactam (250 mg every 12 hours)
Study: 6220603
Drug: Tobramycin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1.0 mg/kg every eight hours)
Study: 28869119
Drug: Home-based pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based pulmonary rehabilitation (3 sessions weekly for 8 weeks, aerobic exercise for 20min at 60-80% max stepping rate, resistance training with elastic band at 70% max voluntary isometric contraction)
Study: 26375919
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise (CONCEX)
Study: 23208878
Drug: New live
Approvals — FDA: no, EMA: no, PMDA: no
Description: New live tetravalent dengue virus vaccine
Study: 21810233
Drug: NEURAPAS® balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEURAPAS® balance (6 tablets)
Study: 19371497
Drug: Lorazepam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (8 mg/day)
Study: 19371497
Drug: Chlordiazepoxide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (80 mg/day)
Study: 16413241
Drug: AVE7688 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE7688 25 mg
Study: 16413241
Drug: AVE7688 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE7688 5 mg
Study: 15571611
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder 1 g/day for 5 days
Study: 15571611
Drug: Metoclopramide (oral)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (oral) for 4 days after placebo on the first day
Study: 9339153
Drug: HVB suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVB suppositories
Study: 9339153
Drug: PGB suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB suppositories
Study: 8232678
Drug: HELP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HELP treatment
Study: 26694377
Drug: Continuous Erythropoietin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Erythropoietin Receptor Activator (CERA)
Study: 8281355
Drug: Perennial immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perennial immunotherapy (602 BU cumulative dose)
Study: 8281355
Drug: Seasonal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal immunotherapy (372 BU cumulative dose)
Study: 28578704
Drug: Marine Phospholipids
Normalized name: marine phospholipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine Phospholipids (MPL) supplementation at 0.3 g of n-3-fatty acids per day for six weeks
Study: 28578704
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) supplementation at 0.3 g of n-3-fatty acids per day for six weeks
Study: 16344336
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (75 mg hydroalcoholic gel applied daily)
Study: 2189617
Drug: Quinapril (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20, 40, 80 mg/day, once or twice daily)
Study: 2189617
Drug: Quinapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10-40 mg/day, once or twice daily)
Study: 2189617
Drug: Quinapril (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10, 20, and 40 mg/day, with optional titration)